Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Morphotek, a subsidiary of Eisai Corporation of North America, has commenced a multi-centered Phase II study of its MORAb-009 monoclonal antibody in mesothelioma.
Subscribe to our email newsletter
The study will evaluate MORAb-009, plus the chemotherapy drugs pemetrexed and cisplatinum, as a first-line treatment for patients with mesothelioma.
The primary objective of the study is to assess the efficacy of MORAb-009 as combination therapy with the current standard of care as determined by progression-free survival in patients with locally advanced malignant pleural mesothelioma.
Secondary objectives include safety and anti-tumor activity of MORAb-009 as determined by objective response rate. The patient population includes individuals with locally advanced malignant pleural mesothelioma who have not received any prior treatment for their disease. Morphotek expects to enroll up to 86 patients in this clinical study, which is being conducted at clinical centers globally.
Martin Phillips, chief medical officer of Morphotek, said: “We are excited to have initiated this Phase II study of MORAb-009 in mesothelioma in cooperation with leading physician-scientists. Mesothelioma has a generally poor prognosis, so we hope that MORAb-009 will one day provide a benefit and hope to mesothelioma cancer patients.”